List of Excipients in Branded Drug ADVIL SINUS CONGESTION AND PAIN RELIEF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Navajo Manufacturing Company Inc	ADVIL SINUS CONGESTION AND PAIN RELIEF	ibuprofen, phenylephrine hydrochloride	67751-150	ACESULFAME POTASSIUM
Navajo Manufacturing Company Inc	ADVIL SINUS CONGESTION AND PAIN RELIEF	ibuprofen, phenylephrine hydrochloride	67751-150	CARNAUBA WAX
Navajo Manufacturing Company Inc	ADVIL SINUS CONGESTION AND PAIN RELIEF	ibuprofen, phenylephrine hydrochloride	67751-150	CELLULOSE, MICROCRYSTALLINE
Navajo Manufacturing Company Inc	ADVIL SINUS CONGESTION AND PAIN RELIEF	ibuprofen, phenylephrine hydrochloride	67751-150	CROSCARMELLOSE SODIUM
Navajo Manufacturing Company Inc	ADVIL SINUS CONGESTION AND PAIN RELIEF	ibuprofen, phenylephrine hydrochloride	67751-150	GLYCERIN
Navajo Manufacturing Company Inc	ADVIL SINUS CONGESTION AND PAIN RELIEF	ibuprofen, phenylephrine hydrochloride	67751-150	HYPROMELLOSE
Navajo Manufacturing Company Inc	ADVIL SINUS CONGESTION AND PAIN RELIEF	ibuprofen, phenylephrine hydrochloride	67751-150	LACTIC ACID

Advil Sinus Congestion and Pain Relief Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Advil Sinus Congestion and Pain Relief is an OTC combination product containing ibuprofen 200 mg and phenylephrine hydrochloride 10 mg per caplet. Its excipient strategy is conventional for an immediate-release solid oral dosage form: direct-compression or granulation aids, disintegrants, film-coating materials, lubricants, and color or appearance agents. The largest commercial opportunity is not a new active-ingredient patent position. It is a reformulated, differentiated OTC product that improves swallowability, dissolution, tolerability, dose convenience, and regulatory resilience as FDA reviews the effectiveness of oral phenylephrine.

The product’s commercial position is exposed to four factors:

1. Ibuprofen has long been generic and widely available.
2. Oral phenylephrine is subject to an FDA effectiveness challenge.
3. The product is primarily protected by brand, packaging, retailer placement, formulation know-how, and regulatory execution rather than a strong molecule-specific patent estate.
4. Excipient innovation can support line extensions, but most conventional excipients will not create meaningful exclusivity by themselves.

What active ingredients and dosage form does Advil Sinus Congestion and Pain Relief use?

Advil Sinus Congestion and Pain Relief combines an analgesic and antipyretic with a nasal decongestant.

Attribute	Product characteristic
Brand	Advil Sinus Congestion and Pain Relief
Active ingredient 1	Ibuprofen 200 mg
Active ingredient 2	Phenylephrine hydrochloride 10 mg
Dosage form	Immediate-release oral caplet or tablet presentation
Therapeutic category	Analgesic, antipyretic, and nasal decongestant
Primary use claims	Temporary relief of sinus pressure, headache, minor aches, fever, and nasal or sinus congestion
U.S. regulatory route	OTC drug labeling under FDA monograph or monograph-related OTC requirements
Commercial owner	Advil brand marketed by Haleon in the United States
Prescription status	Nonprescription

The formulation must deliver two actives with different physicochemical and dose characteristics. Ibuprofen is a poorly water-soluble, relatively high-dose active. Phenylephrine hydrochloride is used at a much lower dose and is readily water soluble. The excipient system therefore has to support content uniformity for phenylephrine while promoting acceptable wetting and dissolution of ibuprofen.

The product is not a modified-release medicine. Excipient selection should prioritize rapid disintegration, consistent dissolution, tablet robustness, and low manufacturing variability.

What excipients are used in Advil Sinus Congestion and Pain Relief?

Public labeling identifies inactive ingredients for the marketed presentation. Commercial formulations can vary by strength, caplet design, manufacturing site, market, and packaging configuration. The labeled excipient system generally includes the following functional classes.

Excipient class	Typical function in the product
Microcrystalline cellulose	Diluent, compression aid, and tablet structure
Croscarmellose sodium	Superdisintegrant that promotes tablet breakup
Sodium starch glycolate	Disintegration and water uptake
Povidone	Binder and granulation aid
Colloidal silicon dioxide	Glidant and moisture-flow control
Stearic acid or related lubricant	Tablet ejection and tooling protection
Hypromellose	Film-coating polymer
Polyethylene glycol	Plasticizer or coating modifier
Polysorbate 80	Wetting or coating aid
Titanium dioxide or other pigments	Opacity and appearance control
Sucrose or other coating solids	Coating and surface finish, where used

The exact inactive-ingredient declaration should be taken from the current package label or DailyMed record for the specific NDC and presentation. DailyMed and the FDA Drug Facts label are the controlling sources for the marketed formulation, not a generic description of Advil products as a brand family. [1]

How does the excipient system support ibuprofen dissolution?

Ibuprofen has limited aqueous solubility. The formulation therefore benefits from:

• Fine particle-size control.
• High-surface-area diluents.
• Rapid tablet disintegration.
• Wetting agents where compatible with stability and taste.
• Controlled compression force.
• Appropriate granulation moisture.
• Dissolution testing that evaluates both ibuprofen and phenylephrine.

A formulation that is over-lubricated or compressed too hard can delay disintegration and reduce ibuprofen dissolution. Magnesium stearate, stearic acid, and hydrophobic coating components require particular process control because excessive hydrophobicity can impair wetting.

How does the formulation maintain phenylephrine content uniformity?

Phenylephrine hydrochloride is present at a much lower mass than ibuprofen. Blend uniformity is therefore a central manufacturing issue. The formulation may use:

• Ordered mixing or geometric dilution.
• A pre-blend of phenylephrine with a portion of microcrystalline cellulose.
• Granulation to reduce segregation.
• Controlled particle-size distributions.
• In-process blend sampling.
• Low-shear transfer and hopper-flow controls.

The main excipient opportunity is not simply adding more disintegrant. It is designing a blend and process that prevent phenylephrine segregation while preserving rapid release of ibuprofen.

What formulation patents protect Advil Sinus Congestion and Pain Relief?

No strong, product-specific U.S. patent barrier is generally associated with the conventional ibuprofen 200 mg and phenylephrine hydrochloride 10 mg immediate-release combination. Ibuprofen and phenylephrine are established active ingredients, and generic manufacturers can make similar combinations subject to applicable FDA requirements.

The principal commercial protections are likely to be:

Protection type	Relevance
Advil trademark	High commercial value and consumer recognition
Trade dress and packaging	Retail differentiation and brand protection
Product label	Controls permitted OTC claims and consumer instructions
Manufacturing know-how	Blend uniformity, coating, dissolution, and stability
Supplier qualification	Can reduce operational risk but is not exclusivity
Formulation patent	Potentially relevant only if a novel delivery, stability, or sensory system is claimed
Regulatory compliance	Creates execution barriers but not market exclusivity
Retail distribution	Supports shelf placement and repeat purchase

Conventional excipients such as microcrystalline cellulose, croscarmellose sodium, povidone, and colloidal silicon dioxide are not likely to create meaningful patent protection in their ordinary use. A defensible patent position would need to claim a specific formulation architecture, process parameter, dissolution profile, stability result, or consumer-relevant performance advantage.

When does Advil Sinus Congestion and Pain Relief lose exclusivity?

The product does not have a conventional small-molecule patent-expiration event comparable to a prescription drug. Ibuprofen and phenylephrine are available to multiple OTC manufacturers, and combination products can be marketed by competitors under applicable FDA requirements.

Exclusivity factor	Current commercial effect
Ibuprofen composition-of-matter exclusivity	None of practical relevance
Phenylephrine composition-of-matter exclusivity	None of practical relevance
Combination-product exclusivity	Generally limited without a qualifying novel formulation
FDA OTC pathway	Allows broad competitive substitution
Brand exclusivity	Continues through trademark, marketing, and distribution
Formulation know-how	Can provide operational advantages
Retail and private-label competition	Persistent and significant

Generic and store-brand competitors can compete on price, pack count, tablet count, and retailer placement. The branded product’s premium depends on consumer trust, recognition, availability, and perceived symptom coverage.

What is the FDA regulatory status of oral phenylephrine?

FDA has proposed that oral phenylephrine is not generally recognized as effective for nasal congestion at the OTC monograph dosage. FDA’s action was based on its review of available data and did not represent a finding that oral phenylephrine is unsafe at labeled conditions of use. The proposal creates a regulatory risk for combination products that rely on oral phenylephrine as the decongestant component. [2]

The regulatory consequences depend on the final FDA action and its implementation terms. Potential outcomes include:

1. Removal of oral phenylephrine from the permitted OTC monograph conditions.
2. Reformulation with another decongestant.
3. Repositioning toward analgesic and sinus-pressure claims supported by ibuprofen.
4. Discontinuation of the combination presentation.
5. Introduction of a new dosage form or separate nasal-decongestant product.

This is the most important commercial variable for Advil Sinus Congestion and Pain Relief. Any excipient strategy should preserve optionality for a reformulation rather than optimize only for the current phenylephrine product.

What excipient opportunities exist for a reformulated product?

1. Fast-dissolving ibuprofen caplet

A reformulated product could use a high-functionality direct-compression platform with:

• Co-processed cellulose-based excipients.
• Superdisintegrant combinations.
• Improved ibuprofen wetting.
• Lower compression-force variability.
• A thinner caplet profile.

The commercial proposition would be faster tablet breakup and improved swallowability. A patent could be considered for a defined excipient ratio, manufacturing process, or dissolution profile if supported by comparative data.

2. Liquid-filled or softgel delivery

Ibuprofen is commonly used in liquid-filled softgels, where the active is solubilized or dispersed in a lipid vehicle. A sinus product using a softgel could provide a differentiated dosage form, but combining ibuprofen with phenylephrine introduces compatibility, fill-volume, and stability challenges.

Potential advantages include:

• Easier swallowing.
• Distinct consumer positioning.
• Potentially faster ibuprofen availability.
• Premium pricing.

Potential barriers include liquid-fill stability, phenylephrine solubility and compatibility, capsule-shell performance, oxygen and moisture control, and higher manufacturing cost.

3. Orally disintegrating or chewable format

An orally disintegrating tablet or chewable tablet could target consumers who have difficulty swallowing caplets. The main development issues are taste masking, dose uniformity, moisture sensitivity, and the bitter or medicinal taste profile associated with the active ingredients.

Excipient options include:

• Mannitol for mouthfeel.
• Crospovidone or croscarmellose sodium for rapid breakup.
• Flavor systems.
• Ion-exchange resins or polymeric taste-masking systems.
• Moisture-barrier packaging.

This format has greater potential for a genuine formulation patent than a standard caplet, particularly if the product achieves a defined disintegration time without compromising stability.

4. Low-sugar or sugar-free coating

A lower-sugar coating can support consumers seeking reduced excipient load or a cleaner label. The commercial benefit is likely modest unless linked to a broader brand proposition. Coating changes must not impair dissolution, increase friability, or produce unacceptable tablet tackiness.

5. Moisture- and heat-stable packaging

Packaging is not an excipient strategy, but it is closely linked to formulation performance. Blister packaging, high-barrier bottles, desiccants, and oxygen-control systems can protect phenylephrine and coating components from environmental stress. Packaging-based differentiation can be more practical than a complex excipient change when the primary need is shelf-life or appearance control.

How strong is the patent estate for Advil Sinus Congestion and Pain Relief?

The estate is likely weak for blocking generic entry and stronger for brand-level commercial defense.

Patent-estate dimension	Assessment
Active ingredients	Weak; mature and broadly available
Standard immediate-release caplet	Weak unless a specific proprietary process is claimed
Novel formulation platform	Potentially moderate
Taste-masked or orally disintegrating version	Potentially moderate to strong if technically differentiated
Softgel or liquid-filled system	Potentially moderate
Manufacturing process	Narrow but potentially useful
Trademark and trade dress	Stronger than active-ingredient patent protection
Regulatory exclusivity	Limited relative to prescription products

A new patent filing would need to avoid claiming only routine excipient substitution. Stronger claim strategies could cover:

• A defined ibuprofen particle-size distribution.
• A phenylephrine uniformity threshold.
• A specified disintegration and dissolution profile.
• A moisture-stable coating system.
• A taste-masked dosage form.
• A softgel fill composition.
• A process that limits segregation during high-speed compression.
• A multi-layer tablet separating incompatible components.

Patentability would depend on unexpected performance, not merely the presence of known excipients.

Which companies are challenging or competing with Advil Sinus Congestion and Pain Relief?

The competitive field includes branded OTC manufacturers, generic drug companies, retailer private labels, and alternative symptom-management products.

Competitor category	Examples
Branded combination products	Sudafed, Tylenol Sinus, Mucinex Sinus-Max, store-branded equivalents
Ibuprofen products	Motrin, generic ibuprofen, retailer private labels
Phenylephrine products	Sudafed PE and private-label phenylephrine products
Alternative decongestants	Products containing pseudoephedrine, subject to sales controls
Nasal products	Oxymetazoline and other topical nasal decongestants
Non-drug alternatives	Saline sprays, humidification products, and sinus irrigation systems

The FDA’s phenylephrine review could shift demand toward pseudoephedrine-containing products, topical nasal decongestants, saline products, or analgesic-only products. Retailers may favor private-label reformulations because they can replace a phenylephrine combination quickly and at lower prices.

What licensing deals could support commercial expansion?

Licensing opportunities are more likely to involve delivery technology than the existing active ingredients. Relevant targets include:

• Co-processed excipient platforms.
• Ibuprofen solubilization systems.
• Taste-masking technologies.
• Orally disintegrating tablet platforms.
• Softgel fill technologies.
• Moisture-barrier coatings.
• Continuous manufacturing and blend-uniformity systems.
• Child-resistant, unit-dose packaging.

A licensing transaction would be commercially attractive only if the technology provides measurable value in one of four areas: faster release, better consumer compliance, lower manufacturing cost, or regulatory continuity after a phenylephrine decision.

A routine excipient license would have limited strategic value because the underlying actives and basic caplet technology are widely available.

What generic launch risks exist?

Generic entry risk is high because the active ingredients are mature and the product does not rely on a conventional patent cliff. The main barriers are commercial rather than legal.

Generic launch scenarios

Scenario	Likely market effect
Current phenylephrine combination remains permitted	Continued price competition and private-label substitution
Oral phenylephrine is removed from OTC monograph	Rapid reformulation and possible product discontinuation
Brand launches ibuprofen-only sinus product	Retains some Advil demand but loses decongestant combination positioning
Brand adopts another decongestant	New regulatory, supply, labeling, and excipient requirements
Retailers shift to private label	Margin compression and reduced shelf allocation
Premium dosage form launches	Potentially protects pricing through differentiation rather than exclusivity

A generic manufacturer can compete without challenging a patent if no blocking patent applies. Paragraph IV litigation is therefore not expected to be the primary entry mechanism for the conventional OTC combination. Paragraph IV certifications are more relevant if a future branded reformulation receives an Orange Book-listed patent.

What is the Orange Book status of Advil Sinus Congestion and Pain Relief?

The product is an OTC medicine rather than a conventional prescription drug approved through an NDA with an Orange Book patent listing. The Orange Book is therefore not expected to provide the same patent-certification framework that applies to prescription combination products.

The absence of a meaningful Orange Book barrier does not eliminate all legal risk. Competitors remain subject to:

• FDA OTC requirements.
• Labeling restrictions.
• Trademark law.
• Trade-dress claims.
• Unfair-competition rules.
• Product-liability exposure.
• Any applicable formulation or manufacturing patents.

For a future NDA-based reformulation, Orange Book listing and Paragraph IV strategy could become relevant, but that would be a different regulatory pathway from the established OTC product.

What manufacturing and IP barriers matter most?

The most material barriers are operational:

1. Maintaining phenylephrine content uniformity at low dosage.
2. Controlling ibuprofen dissolution despite poor water solubility.
3. Preventing segregation during scale-up and packaging.
4. Managing coating and tablet appearance.
5. Demonstrating stability under heat and humidity.
6. Qualifying suppliers for functional excipients.
7. Maintaining high-speed compression performance.
8. Avoiding excipient changes that trigger regulatory or labeling complications.

These barriers can support trade secrets and process know-how. They are harder to enforce than patents but can reduce competitor speed and improve supply reliability.

How does Advil Sinus Congestion and Pain Relief compare with competing dosage forms?

Product approach	Main advantage	Main weakness	Excipient opportunity
Standard caplet	Low cost and familiar use	Limited differentiation	Fast disintegration and improved coating
Softgel	Easy swallowing and premium positioning	Higher cost and compatibility risk	Solubilization and shell-stability systems
Chewable tablet	Accessible dosage form	Taste and texture problems	Taste masking and mouthfeel
Orally disintegrating tablet	Rapid administration without water	Moisture sensitivity	Porous matrix and moisture-barrier packaging
Liquid	Flexible dosing	Stability, taste, and packaging burden	Suspending and flavor systems
Nasal product	Direct local decongestant delivery	Separate device and use experience	Spray-performance and preservative systems

The strongest near-term commercial concept is a differentiated ibuprofen dosage form that does not depend on oral phenylephrine. That strategy reduces exposure to the FDA effectiveness review while preserving the Advil brand’s analgesic equity.

Key Takeaways

• Advil Sinus Congestion and Pain Relief contains ibuprofen 200 mg and phenylephrine hydrochloride 10 mg per dosage unit.
• Its conventional excipient system supports immediate release, tablet strength, blend uniformity, and coating performance.
• Standard excipients do not create a strong blocking patent position.
• The product has greater protection from brand recognition, trade dress, distribution, and manufacturing know-how than from active-ingredient patents.
• FDA’s proposed action on oral phenylephrine is the principal regulatory and commercial risk. [2]
• Reformulation opportunities include fast-dissolving caplets, softgels, chewables, orally disintegrating tablets, and ibuprofen-only sinus products.
• The strongest patent opportunities would involve defined performance characteristics, taste masking, multi-layer systems, solubilization, or manufacturing controls.
• Paragraph IV litigation and Orange Book barriers are unlikely to be central for the existing OTC combination.
• Generic and private-label competition can enter primarily through price, packaging, and retail distribution.
• Commercial investment should favor regulatory-flexible dosage forms and excipient platforms that preserve ibuprofen performance without relying on oral phenylephrine.

FAQs About Advil Sinus Congestion and Pain Relief Excipient Strategy

Can a new excipient composition receive a patent for an ibuprofen sinus product?

Yes, but routine substitution of one conventional excipient for another is unlikely to provide strong patent protection. A patent application would need a novel formulation or process with reproducible and unexpected results.

Is phenylephrine the main regulatory risk for this product?

Yes. FDA has proposed that oral phenylephrine is not effective for nasal congestion under OTC monograph conditions. The final regulatory outcome will determine whether the combination can continue in its current form. [2]

Could an ibuprofen-only product replace Advil Sinus Congestion and Pain Relief?

It could address pain, headache, fever, and sinus-pressure symptoms, but it would not provide the same decongestant positioning. The product would require carefully framed OTC claims and a revised consumer value proposition.

Are excipient suppliers potential licensing targets?

Yes. The most relevant targets would provide differentiated delivery, taste masking, dissolution enhancement, moisture protection, or manufacturing-process control rather than basic commodity excipients.

Would a softgel have stronger commercial protection than a caplet?

A softgel could provide greater product differentiation and potentially support formulation patents, but it would also introduce higher manufacturing cost, stability requirements, and compatibility risks. Its commercial advantage would depend on demonstrated consumer or pharmacokinetic benefits.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Advil Sinus Congestion and Pain Relief drug label. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Proposal to withdraw oral phenylephrine from the over-the-counter monograph as a nasal decongestant. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-safety-and-availability/fda-proposes-removal-oral-phenylephrine-over-counter-monograph-nasal-decongestant

3. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/over-counter-otc-drug-monograph-system

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book